INHAUH

Education

2007.02
Bachelor of Medicine : Hanyang University
2012.02
Master of Medicine : Sungkyunkwan University

Career

2022.03 ~ present
Associate Professor in Hematology and Oncology, Inha University Hospital
2018.01 ~ 2022.02
Assistant Professor in Hematology and Oncology, Inha University Hospital
2016.01 ~ 2018.01
Fellow, Inha University Hospital
2015.03 ~ 2015.12
Fellow, Samsung Medical Center
2008.03 ~ 2012.02
Resident, Samsung Medical Center
2007.03 ~ 2008.02
Intern, Hanyang University Medical Center

Professional Activities

-
a regular member of the Korean Cancer Society
-
a member of Clinical Society for Integrative Oncology
-
a member of the Korean Society of Hematology

Honors

Research & Publications

2018
Cho J, Kim SJ, Park S, Yoo KH, Ki CS, Ko Y, et al. Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma. Ann Hematol. 2018.
2018
Park M, Kim M, Park J, Cho J. Life-Threatening Thrombocytopenia Following Intravenous Contrast Media Infusion. Yonsei Med J. 2018;59(1):158-61.
2018
Kim J, Cho J, Lee MH, Lim JH. Relative Efficacy of Checkpoint Inhibitors for Advanced NSCLC According to Programmed Death-Ligand-1 Expression: A Systematic Review and Network Meta-Analysis. Scientific reports. 2018;8(1):11738.
2018
Cho J, Kim HS, Ku BM, Choi YL, Cristescu R, Han J, et al. Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018:Jco2017773184.
2018
Kim EK, Cho J, Kim JY, Chang SA, Park SJ, Choi JO, et al. Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data. Cancer research and treatment : official journal of Korean Cancer Association. 2018.
2018
Yoo KH, Lee SJ, Cho J, Lee KH, Park KU, Kim KH, et al. A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13. Cancer research and treatment : official journal of Korean Cancer Association. 2018.
2017
Cho J, Kim SY, Kim YJ, Sim MH, Kim ST, Kim NKD, et al. Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma. Clin Transl Oncol. 2017;19(10):1247-52.
2017
Lim SH, Hong JY, Lim ST, Hong H, Arnoud J, Zhao W, et al. Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease. Ann Oncol. 2017;28(9):2199-205.
2016
Lee JY, Lee I, Chang WJ, Ahn SM, Lim SH, Kim HS, et al. MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis. Oncotarget. 2016;7(28):43492-503.
2016
Song HN, Jung KS, Yoo KH, Cho J, Lee JY, Lim SH, et al. Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer. J Thorac Oncol. 2016;11(4):e45-7.
2016
Kim HK, Lee S, Kim K, Heo MH, Lee H, Cho J, et al. Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma. Transl Oncol. 2016;9(6):557-64.
2016
Kim HK, Ham JS, Byeon S, Yoo KH, Jung KS, Song HN, et al. Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea. Cancer research and treatment : official journal of Korean Cancer Association. 2016;48(4):1382-8.
2016
Cho J, Lee J, Kim J, Kim ST, Lee S, Kim SY, et al. Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma. Transl Oncol. 2016;9(5):466-71.
2016
Cho J, Ahn S, Yoo KH, Kim JH, Choi SH, Jang KT, et al. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry. Invest New Drugs. 2016;34(6):677-84.
2013
Cho JH, Kim NJ, Ko SM, Kim C, Ahn HK, Yun J, et al. A case report of paraneoplastic pemphigus associated with esophageal squamous cell carcinoma. Cancer research and treatment : official journal of Korean Cancer Association. 2013;45(1):70-3.
2012
Jung HA, Park S, Cho JH, Kim S, Ko YH, Kim SJ, et al. Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: results from a prospective cohort study. Ann Hematol. 2012;91(11):1747-56.
2012
Cho JH, Kim KM, Kwon M, Kim JH, Lee J. Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs. 2012;30(5):2008-14.
2010
Park S, Lee J, Park SH, Park JO, Kang WK, Park YS, et al. Treatment of hemodialyzed patients with sunitinib in renal cell carcinoma. Chemotherapy. 2010;56(6):485-91.

Etc.

페이지 위치 알려주기